Poli Industria Chimica Spa

Proter S.p.a.

Germano Coppi

Stefano Poli

Lucio Del Corona

Mario Ercole Scevola

Leone Dall'Asta

Cesare Busetti

Giovanni Signorelli

Vanna Springolo

A liquid pharmaceutical composition which can be administered as a foam by means of suitable supplying devices, without necessity of gas propeller, said composition consisting of:

Oral, cutaneous and intravaginal pharmaceutical compositions in the form

N-(5-thioxo-L-prolyl)-L-cysteine and derivatives thereof, having interesting mucolytic-expectorant, antioxidant (radical-scavenger), antielastase, antiemphysema, immunostimulating and hepatoprotective activities and a low toxicity are described, as well as processes for the preparation thereof and pharmaceutical formulations for the use in therapy.

N-(5-thioxo-L-prolyl)-L-cysteine, derivatives thereof, processes for the

3-L-(5-thioxo-L-prolyl)thiazolidine-4-carboxylic acid and the derivatives thereof have valuable immunostimulating, antioxidant, antiradical and antiageing properties. They are prepared by thionating the corresponding 3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid derivatives or by condensing 5-thioxo-L-proline with the corresponding L-thiazolidine-4-carboxylic acid derivatives.

3-L-(5-thioxo-L-prolyl)thiazolidine-4-carboxylic acid and derivatives

Ester or amide derivatives of 3-pyroglutamylthiazolidine-4-carboxylic acid exhibit interesting immunostimulating, antitoxic, antiinflammatory, antioxidental, antiageing properties.

Derivatives of thiazolidine-4-carboxylic acid, its preparation and

New N-(2-cycloalkylamino)ethyl-substituted benzamides having a powerful stimulating activity on gastric motility and with a low central anti-dopaminergic activity are described. The synthesis and the pharmaceutical preparation for therapeutical use are also described.

N-cycloalkylaminoethylbenzamide derivatives, their synthesis and

A therapeutic treatment for the athrosis diseases comprising administering by intraarticular route from 1 to 5 ml of an aqueous solution containing from 10 to 50 mg of a diacetyl rhein salt having formula (I): ##STR1## wherein M represents an alkali or an earth alkali metal or the residue of an organic base. The diacetyl rhein salts administered by intraarticular route exhibit higher pharmacological activity than the corresponding diacetylrhein administered orally.

Diacetylrhein salts and their therapeutical use in the treatment of

Several methods are disclosed for the preparation of oral pharmaceutical forms with delayed release of rhein and its derivatives. The pharmaceutically active ingredient is provided in the form of granules, coated with at least one of polyvinylpyrrolidone, shellac and hydroxypropylmethyl cellulose. The desired effect of the coating is to slow release of the pharmaceutically active ingredient by resisting gastric juices in the stomach, but gradually dissolving in the intestines.

Growing community of inventors

Milan, Italy

Germano Coppi